Sirnaomics

https://www.sirnaomics.com/

Last activity: 08.09.2025

Active

Categories: AestheticsBiopharmaOncologyRNAiTherapeutics

Sirnaomics is leveraging an unsurpassed level of knowledge and experience in RNA interference (RNAi) technology and forging a path to high value creation with exciting clinical product development programs in multiple therapeutic areas. Sirnaomics, Inc. was established in 2007 by a group of leading scientists from top US pharmaceutical companies.

Our management team has combined over 100 years experience in the biopharmaceutical industries with special expertise in RNAi and delivery system technologies. We have partnered with NIH, NAVY MRC, Johns Hopkins, Duke, University of Maryland and Penn State University. This work has advanced our product development and preclinical programs and we are now ready to move forward with our clinical development strategy. The vast experience of our scientific and management teams ensures that our therapeutics are developed with the highest quality of scientific validity and supported by a solid intellectual property portfolio. We feel this gives us a significant advantage in both the safety and efficacy of our therapeutics as we move forward and execute our clinical programs in US, EU, and China.

Twitter Facebook LinkedIn Email

Likes

Followers

4.73K

Mentions

Overview

Location

Hong Kong

Employees

51-200

Phone

+1 301-740-1730

Total raised

$292M

Founded date

2007

Funding Rounds 5

Date	Series	Amount	Investors
Sign up to see	Sign up to see	Sign up to see	Sign up to see
Oct 27, 2020	Series D round	$105M
Apr 29, 2019	Series C round	$47M
Jun 8, 2018	Series C round	$25M
May 4, 2016	Series B round	$10M

Mentions in press and media 97

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Oct 4, 2024	Sirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and Development	HONG KONG, GERMANTOWN, Md., and SUZHOU, China,, Oct. 4, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257.HK), a leading biopharm...
Sep 19, 2024	Sirnaomics Announces Demonstration of a Novel Mechanism of Action of Its siRNA Therapeutics for Focal Fat Reduction in Journal of Cosmetic Dermatology	HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Sept. 19, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmac...
Aug 1, 2024	Sirnaomics Announces a Partnership with Gore Range Capital for Establishment of a JV, Sagesse Bio, to Advance Its RNAi Therapeutics into Aesthetic Medicine	HONG KONG, GERMANTOWN, Md. and SUZHOU, China, Aug. 1, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceut...
Jul 12, 2024	Sirnaomics Announces Completion of IND-Enabling Studies of Safety and Efficacy for STP125G with NHP Models, Targeting ApoC3 for Treatment of Cardiovascular Diseases	HONG KONG, GERMANTOWN, Md. and SUZHOU, China, July 12, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharma...
Jul 8, 2024	Sirnaomics Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Therapeutics	HONG KONG and GERMANTOWN, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmac...
Jun 28, 2024	Sirnaomics Announces Completion of STP707 Phase I Clinical Study with Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer Patients	HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 28, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceu...
Jun 13, 2024	Sirnaomics Demonstrates Strong Antitumor Activity of Its Novel Oligonucleotide-ChemoDrug Conjugate in Journal of Oncology Research and Therapy	HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 13, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceu...
Mar 28, 2024	Sirnaomics Announces 2023 Annual Results	Focuses on the Consolidation for Leading Projects Accelerates Clinical Trials for Core Products STP705, STP707 and STP122G HONG KONG, Germantown, Md. and SUZHOU, China, March 28, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"...
Jan 24, 2024	Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors	Study published in NAR Cancer, a leading peer-reviewed journal in the field of nucleic acid therapeutics HONG KONG, Germantown, Md. and SUZHOU, China, Jan. 24, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257,...
Dec 18, 2023	RNAimmune Receives Investigational New Drug Application Clearance from U.S. FDA for mRNA-Based Respiratory Syncytial Virus Vaccine RV-1770	GERMANTOWN, Md and GUANGZHOU, China, Dec. 18, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical com...
Dec 6, 2023	Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment	HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, Dec. 6, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading bio...
Dec 1, 2023	Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer	HONG KONG, Germantown, Md. and Suzhou, China, Dec. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceut...
Nov 1, 2023	Sirnaomics Presents Positive Clinical Data of STP705 for Focal Fat Reduction	The Group is Advancing the Program to a Phase II Clinical Study Data presented at the 2023 Fall Clinical Dermatology Conference HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, Nov. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "...
Aug 31, 2023	Sirnaomics Announces Successful Phase I Clinical Study of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors	Six cohorts, totaling 50 late-stage cancer patients, received STP707 four times monthly by intravenous infusion at escalating dosages. All cohorts demonstrated a strong safety profile with no dose-limiting toxicity noted for any dosing coho...
Aug 31, 2023	Sirnaomics Announces 2023 Interim Results	Positive Clinical Readouts Validate Potential of Proprietary Delivery Platforms and Cement Global Leadership in RNAi Therapeutics Business Highlights Promising progress in clinical development After an End of Phase-II meeting and with guida...
Jul 28, 2023	Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Development	HONG KONG, Germantown, Md. and SUZHOU, China, July 28, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharma...
Jul 12, 2023	Sirnaomics to Present Latest Developments on Two Proprietary Delivery Platforms at Upcoming Industry Conferences	HONG KONG, Germantown, Md. and SUZHOU, China, July 12, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceu...
Jul 5, 2023	Sirnaomics Establishes a Strategic Partnership with EDIRNA Inc., an RNA-Editing Therapeutic Company	HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, July 5, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading bio...
Jun 19, 2023	Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development	HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 19, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceu...
Jun 14, 2023	Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences	HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 14, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceu...
Jun 5, 2023	Sirnaomics Reports Interim Results of STP705 Phase I Clinical Study for Medical Aesthetics Treatment in Adults Undergoing Abdominoplasty	HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 5, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmac...
Jun 2, 2023	Sirnaomics Dosed the First Patient in Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment	HONG KONG, Germantown, Md. and Suzhou, China, June 2, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceut...
May 17, 2023	Sirnaomics to receive HK$8 million subsidy from the HKSTP Clinical Translational Catalyst Plan	HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, May 17, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading bio...
Apr 12, 2023	Sirnaomics Launches Phase I Clinical Trial for GalNAc Factor XI Program	Study commences following green light from the U.S. FDA for Investigational New Drug Application HONG KONG, GERMANTOWN, Md. and SUZHOU, China, April 12, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, tog...
Mar 28, 2023	Sirnaomics Announces 2022 Annual Results	Significant Progress in Clinical Trials for Core Products Reinforces Leading Position in RNA Therapeutics with Strong Product Pipeline Matrix Business Highlights Clinical development STP705 - The part-one Phase IIb interim data on STP705 fo...
Mar 20, 2023	Sirnaomics to Present Latest Developments in Polypeptide Nanoparticle Platform at the 4th Annual RNAi-Based Therapeutics Summit	HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, March 20, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, and together with its subsidiaries, the "Group" or "Sirnaomics"), a le...
Feb 7, 2023	RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting	HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Feb. 7, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, and together with its subsidiaries, the "Group" or "Sirnaomics"), a leading bioph...
Feb 1, 2023	Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers	HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Feb. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi t...
Feb 1, 2023	Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers	HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Feb. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi t...
Dec 21, 2022	Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors	First three out of five cohorts pass safety requirements, allowing the Company to dose additional cohorts to assess safety, tolerability, pharmacokinetics and anti-tumor activity HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Dec. 21, 2022 ...
Dec 14, 2022	Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ	Dose escalation cohort study is evaluating the safety, tolerability and efficacy of various doses of STP705 administered as intralesional injection in subjects with isSCC GERMANTOWN, Md. and SUZHOU BIOBAY, China, Dec. 14, 2022 /PRNewswire/ ...
Nov 8, 2022	Sirnaomics Doses the First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment	Data results expected to be available in 1H 2023 GAITHERSBURG, Md. and SUZHOU, China, Nov. 8, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company...
Oct 19, 2022	Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences	Sirnaomics Chief Technology Officer Dmitry Samarsky is a featured speaker at the RNA Leaders USA Congress and 18th Drug Discovery Innovation Programme Gaithersburg, Md. and Suzhou, China, Oct. 19, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the &...
Sep 20, 2022	Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference	GAITHERSBURG, Md. and SUZHOU, China, Sept. 20, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeut...
Sep 7, 2022	Sirnaomics to Present at 3rd Annual Jefferies Asia Forum	GAITHERSBURG, Md. and SUZHOU, China, Sept. 7, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeuti...
Aug 29, 2022	Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma	Data showed an excellent safety profile with no adverse events among the five subjects treated. Company continues to explore doses in the ongoing Phase II dose escalation study GAITHERSBURG, Md and SUZHOU, China, Aug. 29, 2022 /PRNewswire/ ...
Aug 26, 2022	Sirnaomics Advances GalAhead(TM)-Based RNAi Therapeutics for Treatment of Complement-Related Diseases	GAITHERSBURG, Md. and SUZHOU, China, Aug. 26, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeuti...
Aug 22, 2022	Sirnaomics Becoming A Constituent of Hang Seng Family of Indexes	HONG KONG, Aug. 22, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that the Com...
Aug 19, 2022	Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ	Data results will be available in Q1 2023 GAITHERSBURG, Md. and SUZHOU, China, Aug. 19, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in di...
Aug 18, 2022	Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ	Data results will be available in Q1 2023 GAITHERSBURG, Md. and SUZHOU, China, Aug. 18, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in di...
Aug 16, 2022	Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM)) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics	A proprietary GalNAc delivery system with enhanced Endosome Escape and Dual-Targeting GAITHERSBURG, Md. and SUZHOU, China, Aug. 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK...
Jul 26, 2022	Sirnaomics Receives IND Clearance from the "Taiwan Ministry of Health and Welfare" for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment	GAITHERSBURG, Md. and SUZHOU, China, July 26, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeuti...
Jun 22, 2022	Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics based on its Proprietary GalAhead™ Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium	GAITHERSBURG, Md. and SUZHOU, China, June 22, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeuti...
Jun 16, 2022	Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology	GAITHERSBURG, Md. and SUZHOU, China, June 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the peer-revi...
May 30, 2022	Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment	GAITHERSBURG, Md. and SUZHOU, China, May 30, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutic...
May 20, 2022	Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit	GAITHERSBURG, Md. and SUZHOU, China, May 20, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutic...
May 11, 2022	Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Programs at the TIDES USA 2022	GAITHERSBURG, Md. and SUZHOU, China, May 11, 2022 /PRNewswire/ -- Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it ...
Apr 4, 2022	Sirnaomics Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis	HONG KONG, April 4, 2022 /PRNewswire/ -- Sirnaomics Ltd. ("Sirnaomics," stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today dose administration for the first...
Mar 30, 2022	RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines	GAITHERSBURG, Md., March 30, 2022 /PRNewswire/ -- RNAimmune, Inc. (the "Company" or "RNAimmune"), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced t...
Mar 15, 2022	Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress	Sirnaomics CTO Dmitry Samarsky, PhD, to Also Present OPT Congress Opening Remarks GAITHERSBURG, Md. and SUZHOU, China, March 15, 2022 /PRNewwire/ -- Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical ...
Mar 15, 2022	Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress	Sirnaomics CTO Dmitry Samarsky, PhD, to Also Present OPT Congress Opening Remarks HONG KONG, March 15, 2022 /PRNewswire/ -- Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and ...
Feb 23, 2022	Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma	HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced interim data from a Phase II clin...
Feb 16, 2022	Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)	HONG KONG, Feb. 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that they ha...
Feb 9, 2022	Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors	HONG KONG, Feb. 9, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the start of ...
Feb 9, 2022	Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors	HONG KONG, Feb. 9, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the start of ...
Jul 14, 2021	Sirnaomics Doses First Patient in Phase 2 Study of STP705 for Keloid Scar Prevention
Jul 2, 2021	Robinhood posts big gains and big risks in its IPO filing	This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content How open source is transforming databases From MongoDB Its origin story is almost as...
Jul 2, 2021	Robinhood posts big gains and big risks in its IPO filing	This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content How to build a cloud strategy you can trust From PwC Its origin story is almost as w...
Jul 1, 2021	Sirnaomics Nabs $105M Series E Round	GAITHERSBURG, MD, Sirnaomics announced today that it has sealed $105 million in a Series E financing. >> Click here for more funding data on Sirnaomics >> To export Sirnaomics funding data to PDF and Excel, click here Sir...
Jul 1, 2021	Sirnaomics Secures $105 Million in Series E Financing
Jun 30, 2021	Sirnaomics Doses First Patient in Phase 2b Study of STP705 for Treatment of Squamous Cell Skin Cancer
Jun 24, 2021	Sirnaomics Doses First Patient in Phase 1 U.S. Clinical Study of STP705 for Treatment of Liver Cancer
Jun 16, 2021	Sirnaomics Announces Acceptance of Investigational New Drug Application by China NMPA for Global Multicenter Phase 2b Trial of STP705 Treatment for Skin Squamous Cell Carcinoma
Apr 25, 2021	Sirnaomics Initiates Phase 2b Study Using STP705 for Treatment of Squamous Cell Skin Cancer
Apr 18, 2021	Sirnaomics Initiates Phase 2 Study Using STP705 for Keloid Scar Prevention
Feb 2, 2021	Sirnaomics to Present at Medical Dermatology Summit
Jan 17, 2021	Sirnaomics Announces First Patient Dosed In Phase 2a Study of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
Dec 20, 2020	Sirnaomics Reports Positive Data from Phase 2a Study of STP705 for Treatment of Squamous Cell Skin Cancer
Oct 29, 2020	Money Moves: These 4 DC-area tech companies secured millions to kick off Q4	Money Moves is a column where we chart the funding raises of tech companies across the region. Have a tip? Email us at [email protected]. Strider Technologies, a D.C.-based developer of software to help companies protect their intellectual pr...
Oct 27, 2020	Biopharmaceutical enterprise Sirnaomics raises US$105 million investment
Oct 26, 2020	Sirnaomics Seals $105M Series D	Sirnaomics has sealed a $105 million Series D financing co-led by Rotating Boulder Fund, Walvax Biotechnology, and Sunshine Riverhead Capital. >> Click here for more funding data on Sirnaomics >> To export Sirnaomics funding...
Oct 26, 2020	Sirnaomics Raises US$105M in Series D Financing	Sirnaomics Inc., a Gaithersburg, Maryland, USA-based biopharmaceutical company in discovery and development of RNAi therapeutics, raised USD$105m in Series D financing. The round was co-led by existing investor Rotating Boulder Fund, new in...
Oct 23, 2020	Chinese investors wager $105M on an IPO-bound biotech looking to push RNAi as mainstream cancer therapy	Shortly after Sirnaomics brought in a $47 million Series C for its small interfering RNA pipeline last year, Patrick Lu — the founder, president and CEO — was asked to outline the scientific advances that will be necessary ...
Oct 23, 2020	Chinese investors pour $105m into US biopharma firm Sirnaomics’s Series D	Premium Sirnaomics Inc, a US-based biopharmaceutical firm focused on the discovery and development of RNAi therapeutics, announced on Friday the completion of a $105 million Series D funding round from Chinese investors. Continue reading th...
Oct 23, 2020	Sirnaomics Seals $105 Million Series D Financing	Sirnaomics Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it has sealed its USD$105 million Series D financing. This round of funding was co-led by existing investor Rotatin...
Oct 23, 2020	Sirnaomics nabs a major $105M funding round for next stage of its RNA work W h i t e p a p e r Vital Precision for Cost Reduction, QA, and Regulatory Compliance	After posting positive results from a midstage test for its RNAi candidate back in the spring, Sirnaomics has grabbed a $105 million series D round. Sponsored by Agilent Technologies How would you like to win free bench space at Lab Central...
Oct 23, 2020	Sirnaomics nabs a major $105M funding round for next stage of its RNA work	After posting positive results from a midstage test for its RNAi candidate back in the spring, Sirnaomics has grabbed a $105 million series D round. The cash boost, co-led by existing investor Rotating Boulder Fund, new investor Walvax Biot...
Oct 22, 2020	Sirnaomics Seals US$105 Million Series D Financing to Fund Development of RNAi Therapeutics for Treatment of Cancers, Fibrotic Diseases and Viral Infections
Apr 29, 2019	Daily funding roundup - April 29th, 2019	Duco raised $1.7M; Specright secured $8.8M; Dyndrite closed $10M; A Cloud Guru landed $33M Duco: Duco is a data engineering technology company that provides self-service data engineering in the cloud. Duco has raised $1.7 million in seed fu...
Apr 29, 2019	Term Sheet — Monday, April 29	GROWTH AT ALL COSTS Good morning, Term Sheet readers — I’m back! Paid Content How can you protect what you can't see? From ExtraHop I read a Wall Street Journal column titled, “Why Investors Don’t Care That Snap and Lyft Are Hemorrhagi...
Apr 29, 2019	Sirnaomics closes second portion of $47M Series C round for RNA-interference drugs	The company plans to use the money to support its clinical and drug-development technology programs. Its most advanced product candidate is STP705, which is in Phase II development for non-melanoma skin cancer and hypertrophic scar reductio...
Apr 26, 2019	Sirnaomics Closes $47M Series C Financing	Sirnaomics Inc., a Gaithesburg, MD-based biopharmaceutical company focused on the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, raised a $22m Series C2 financing round. This round was led by CR-CP Life...
Apr 26, 2019	Sirnaomics Closes $47M in Series C	GAITHERSBURG, MD, Biopharmaceutical company has sealed the C2 round of financing for $22 million. >> Click here for more funding data on Sirnaomics >> To export Sirnaomics funding data to PDF and Excel, click here Sirnaom...
Apr 26, 2019	Sirnaomics Closes $47M Series C Financing	Sirnaomics Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics against cancer and fibrotic diseases, announced today that it has sealed the C2 round of financing for $22 million. This round of funding...
Jun 8, 2018	Sirnaomics raises $25 million in Series C1 round for RNAi drug	The company – which also has operations in the Chinese cities of Guangzhou and Suzhou – will use the funding to expand its clinical RNAi programs in anti-fibrosis and anti-cancer programs. The company’s lead drug candidate is STP705, an siR...
Jun 7, 2018	Term Sheet — Thursday, June 7	BUYING LEGITIMACY Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop Financial terms weren’t disclosed. Here’s what to know about this deal: • This is huge for Coinbase because it could...
Jun 7, 2018	China’s Yuexiu New Industrial Investment leads $18m round for Sirnaomics	Premium China’s Yuexiu New Industrial Investment, a corporate investment arm of Yue Xiu Enterprises (Holdings) Limited, has led a Series C1 financing of $25 million into US-based biopharmaceutical company Sirnaomics Inc. Continue reading th...
Jun 6, 2018	Sirnaomics Raises $25M Series C1	Sirnaomics, Inc., a leading biopharmaceutical company in development of RNAi therapeutics, announces today that it has closed Series C1 financing of US$25 Million(RMB?160 Million). This round of financing was led by Yuexiu New Industrial In...
Jun 6, 2018	Sirnaomics Closes $25M in Series C-1	GAITHERSBURG, MD, Leading biopharmaceutical company in development of RNAi therapeutics, announces today that it has closed Series C1 financing. >> Click here for more funding data on Sirnaomics >> To export Sirnaomics fundi...
Jun 6, 2018	Sirnaomics Closed US$25M Series C1 Financing	Sirnaomics, Inc., a Gaithersburg, Md.-based biopharmaceutical company in development of RNAi therapeutics, closed $25m Series C1 financing. The round was led by Yuexiu New Industrial Investment, followed by Sangel Biomedical Venture Capital...
May 5, 2016	HK’s Value Measured Investment leads $10m round in bio-pharma Sirnaomics	Premium Hong Kong-based venture capital firm Value Measured Investment Ltd. has led a $10-million Series B funding round in Sirnaomics Inc., a Maryland, US-based biopharmaceutical company. Continue reading this story with a subscription to ...
May 4, 2016	Sirnaomics Closes US$10M Series B Funding Round	Sirnaomics, Inc., a Gaithersburg, Maryland,-based biopharmaceutical company focused on the discovery and development of RNAi therapeutics, closed a US$10m Series B funding round. The round was led by Hong Kong based venture capital firm Val...
May 4, 2016	Sirnaomics Raises $10M in Series B	GAITHERSBURG, MD, Leading biopharmaceutical company in discovery and development of RNAi therapeutics, has closed Series B financing of $10 million. >> Click here for more funding data on Sirnaomics >> To export Sirnaomics f...
Nov 23, 2015	New Money: These DC Companies Raised Millions This Week	Like this? Get a daily dose of D.C.-area funding news in The Beat. Sign up here. Here are all of the tech funding deals out of the Washington, D.C., area this week. We’ll be updating this post as more news comes out. Tuesday, November 24 Co...
	Sirnaomics closes second portion of $47M Series C round for RNA-interference drugs	A company developing RNA-interference drugs against cancers and fibrotic diseases has closed its latest round of financing. Sirnaomics – which is headquartered in Gaithersburg, Maryland, and has locations in China – said Friday that it had ...
	Sirnaomics raises $25 million in Series C1 round for RNAi drug	An early-stage company developing RNA-interference therapies for cancers and fibrotic diseases has raised $25 million from several Chinese funds. Gaithersburg, Maryland-based Sirnaomics said Wednesday it had raised the funding – equivalent ...

Reviews 0

FAQ about Sirnaomics

When was Sirnaomics founded?

Sirnaomics was founded in 2007.

How much funding has Sirnaomics raised?

Sirnaomics has raised $292M in total across 5 funding rounds.

What funding rounds has Sirnaomics raised?

Parsers VC lists 5 funding rounds of Sirnaomics, among them a Series D round of $105M on Oct 27, 2020, a Series C round of $47M on Apr 29, 2019 and a Series C round of $25M on Jun 8, 2018.

What has the press written about Sirnaomics?

Parsers VC has collected 97 articles mentioning Sirnaomics, among them “Sirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and Development” (Oct 4, 2024) and “Sirnaomics Announces Demonstration of a Novel Mechanism of Action of Its siRNA Therapeutics for Focal Fat Reduction in Journal of Cosmetic Dermatology” (Sep 19, 2024).

Is Sirnaomics still active?

Yes, Sirnaomics is active; its latest activity on Parsers VC dates from Sep 8, 2025.